Email this article Clinical case of urachal carcinoma treatment
- Authors: Nurgaliyev N.S.1, Ukolova E.A.1, Satbaeva E.B.2, Aydarkulov A.A.1, Rakhimov G.T.1
-
Affiliations:
- Almaty SEMA Hospital
- Almaty Oncology Center
- Issue: Vol 20, No 1 (2024)
- Pages: 140-145
- Section: CLINICAL NOTES
- Published: 17.05.2024
- URL: https://oncourology.abvpress.ru/oncur/article/view/1764
- DOI: https://doi.org/10.17650/1726-9776-2024-20-1-140-145
- ID: 1764
Cite item
Full Text
Abstract
Urachal carcinoma is a rare pathology of the lower urinary tract. In a review of the largest case series, five-year overall survival was about 50 %. The poor prognosis is mainly attributed to advanced stage of the disease due to relative absence of symptoms in localized disease, the difficulty of identification by cystoscopy, and the lack of clear consensus regarding investigation and treatment of localized and advanced disease.
We report a case of treatment of a 46-year-old patient with primary urachal carcinoma. Cystoscopy revealed a lesion on the bladder closer to the apex. Magnetic resonance imaging of the pelvic organs revealed a picture of a malignant neoplasm of the bladder with growth into the paravesical tissue and the anterior wall of the bladder. The patient underwent surgery followed by adjuvant chemotherapy.
About the authors
N. S. Nurgaliyev
Almaty SEMA Hospital
Author for correspondence.
Email: nurgaliyev.ns@gmail.com
ORCID iD: 0000-0001-8473-6645
Nurzhan S. Nurgaliyev.
31 Nauryzbay Batyra St., Almaty 050000
KazakhstanE. A. Ukolova
Almaty SEMA Hospital
Email: kroter_elena@mail.ru
ORCID iD: 0009-0004-1163-5973
31 Nauryzbay Batyra St., Almaty 050000
KazakhstanE. B. Satbaeva
Almaty Oncology Center
Email: somaka@mail.ru
ORCID iD: 0000-0002-1456-0047
7a Utepova St., Almaty 050060
KazakhstanA. A. Aydarkulov
Almaty SEMA Hospital
31 Nauryzbay Batyra St., Almaty 050000
KazakhstanG. T. Rakhimov
Almaty SEMA Hospital
31 Nauryzbay Batyra St., Almaty 050000
KazakhstanReferences
- Begg R.C. Theurachus: itsanatomy, histology and development. J Anat 1930;64:170–83.
- WHO classification of tumours series. 5th edn. Vol. 8. Available at: https://tumourclassification.iarc.who.int/chapters/36.
- Szarvas T., Modos O., Niedworok C. et al. Clinical, prognostic, and therapeutic aspects of urachal carcinoma – a comprehensive review with meta-analysis of 1010 cases. Urol Oncol 2016;34:388–98. doi: 10.1016/j.urolonc.2016.04.012
- https://www.pathologyoutlines.com/topic/bladderadenourachal.html.
- Molina J.R., Quevedo J.F., Furth A.F. et al. Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases. Cancer 2007;110(11):2434–40. doi: 10.1002/cncr.23070
- Siefker-Radtke A. Urachal adenocarcinoma: a clinician’s guide for treatment. Semin Oncol 2012;39(5):619–24. doi: 10.1053/j.seminoncol.2012.08.011
- Sheldon C.A., Clayman R.V., Gonzalez R. et al. Malignant urachal lesions. J Urol 1984;131(1):1–8. doi: 10.1016/s0022-5347(17)50167-6
- Krysiewicz S. Diagnosis of urachal carcinoma by computed tomography and magnetic resonance imaging. Clin Imaging 1990;14(3):251–4. doi: 10.1016/0899-7071(90)90085-p
- Siefker-Radtke A.O., Gee J., Shen Y. et al. Multimodality management of urachal carcinoma: the M.D. Anderson Cancer Center experience. J Urol 2003;169(4):1295–8. doi: 10.1097/01.ju.0000054646.49381.01
- Henly D.R., Farrow G.M., Zincke H. Urachal cancer: role of conservative surgery. Urology 1993;42(6):635–9. doi: 10.1016/0090-4295(93)90526-g
- Mylonas K.S., O’Malley P., Ziogas I.A. et al. Malignant urachal neoplasms: a population-based study and systematic review of literature. Urol Oncol 2017;35(1):33e11–9. doi: 10.1016/j.urolonc.2016.07.021
- Kikuchi M., Kamei S., Morirama Y. et al. Case of urachal cancer treated by neoadjuvant chemotherapywith FOLFOX4 (oxaliplatin, 5-FU and leukovolin). Hinyokika Kiyo 2008;54(8):557–9.
- Kume H., Tomita K., Takahashi S., Fukutani K. Irinotecan as a new agent for urachal cancer. Urol Int 2006;76(3):281–2. doi: 10.1159/000091635
- Galsky M.D., Iasonos A., Mironov S. et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology 2007;69:255–9. doi: 10.1016/j.urology.2006.10.029
- Jung H.A., Sun J.M., Park S.H. et al. Treatment outcome and relevance of palliative chemotherapy in urachalcancer. Chemotherapy 2014;60(2):73–80. doi: 10.1159/000368071
Supplementary files
